TriangleNCT01587703 · OUTCOME
Progression Free Survival-Part 1 BID
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Median of 1.41 months of drug exposure
What was measured
Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.
Analysis population: All Treated Population
Groups in this outcome
Part 1: GSK525762 20 mg BID
Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.
Part 1: GSK525762 30 mg BID
Participants were administered twice daily oral dose of 30 mg GSK525762.
Part 1: GSK525762 40 mg BID
Participants were administered twice daily oral dose of 40 mg GSK525762.
| Group | Source count |
|---|---|
| Part 1: GSK525762 20 mg BID | 4 |
| Part 1: GSK525762 30 mg BID | 10 |
| Part 1: GSK525762 40 mg BID | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: GSK525762 20 mg BID | 7.7 | Not reported | 0.9 | 14.5 | Not reported |
| Part 1: GSK525762 30 mg BID | 5.6 | Not reported | 2.9 | 7.0 | Not reported |
| Part 1: GSK525762 40 mg BID | 8.0 | Not reported | 7.9 | 18.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.9
- upper Limit
- 14.5
- value
- 7.7
- group Id
- OG001
- lower Limit
- 2.9
- upper Limit
- 7.0
- value
- 5.6
- group Id
- OG002
- lower Limit
- 7.9
- upper Limit
- 18.7
- value
- 8.0
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 10
- group Id
- OG002
- value
- 5
- units
- Participants
- description
- Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.
- id
- OG000
- title
- Part 1: GSK525762 20 mg BID
- description
- Participants were administered twice daily oral dose of 30 mg GSK525762.
- id
- OG001
- title
- Part 1: GSK525762 30 mg BID
- description
- Participants were administered twice daily oral dose of 40 mg GSK525762.
- id
- OG002
- title
- Part 1: GSK525762 40 mg BID
- param Type
- MEDIAN
- population Description
- All Treated Population
- reporting Status
- POSTED
- time Frame
- Median of 1.41 months of drug exposure
- title
- Progression Free Survival-Part 1 BID
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice